Results 21 to 30 of about 355,709 (346)
Non-small-cell lung cancer metastasis to unusual sites: A retrospective case series
Cancer Research, Statistics, and Treatment, 2021 Background: The majority of all lung cancers are non-small-cell lung cancers (NSCLCs). They usually spread to the pleura, brain, adrenal gland, lungs, liver, and bones.
Sandip Ganguly +6 more
doaj +1 more source
TMB in NSCLC: A Broken Dream? [PDF]
International Journal of Molecular Sciences, 2021 Although immune checkpoint inhibitors have changed the treatment paradigm of a variety of cancers, including non-small-cell lung cancer, not all patients respond to immunotherapy in the same way. Predictive biomarkers for patient selection are thus needed. Tumor mutation burden (TMB), defined as the total number of somatic/acquired mutations per coding
Sara Bravaccini +2 more
openaire +3 more sources
Atezolizumab for First‐Line Treatment of Metastatic Nonsquamous NSCLC
New England Journal of Medicine, 2018 BACKGROUND The cancer‐cell–killing property of atezolizumab may be enhanced by the blockade of vascular endothelial growth factor–mediated immunosuppression with bevacizumab.
M. Socinski +19 more
semanticscholar +1 more source
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.
New England Journal of Medicine, 2020 BACKGROUND The efficacy and safety of the anti-programmed death ligand 1 (PD-L1) monoclonal antibody atezolizumab, as compared with those of platinum-based chemotherapy, as first-line treatment for patients with metastatic non-small-cell lung cancer ...
R. Herbst +21 more
semanticscholar +1 more source
Anti–PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC
JCI Insight, 2022 Treatment with anti–PD-1 and anti-PD-L1 therapies has shown durable clinical benefit in non–small cell lung cancer (NSCLC). However, patients with NSCLC with epidermal growth factor receptor (EGFR) mutations do not respond as well to treatment as ...
Eric Tu +16 more
semanticscholar +1 more source
Aaptamine attenuates the proliferation and progression of non-small cell lung carcinoma
Pharmaceutical Biology, 2020 Context Aaptamine is a potent ocean-derived non-traditional drug candidate against human cancers. However, the underlying molecular mechanisms governing aaptamine-mediated repression of lung cancer cells remain largely undefined. Objective To examine the
Kaikai Gong +8 more
doaj +1 more source
Cancer Research, Statistics, and Treatment, 2021 Words are the most important and sometimes the only medium of communication between a radiologist and a treating physician. The concept of structured reporting in radiology was well received in the face of growing concerns to overcome the limitations of ...
Abhishek Mahajan
doaj +1 more source
FDA Approval Summary: Sotorasib for KRAS G12C Mutated Metastatic NSCLC.
Clinical Cancer Research, 2021 On May 28, 2021, the U.S. Food and Drug Administration (FDA) granted accelerated approval to sotorasib (Lumakras, Amgen) for the treatment of adults with advanced non-small cell lung cancer (NSCLC) with a Kirsten rat sarcoma proto-oncogene (KRAS) G12C ...
Erica C Nakajima +15 more
semanticscholar +1 more source
Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC
Nature Communications, 2021 Accurately evaluating minimal residual disease (MRD) could facilitate early intervention and personalized adjuvant therapies. Here, using ultradeep targeted next-generation sequencing (NGS), we evaluate the clinical utility of circulating tumor DNA ...
B. Qiu +13 more
semanticscholar +1 more source
Journal of Hematology & Oncology, 2022 Background Transfer RNA-derived fragments (tRFs) are a new class of small non-coding RNAs. Recent studies suggest that tRFs participate in some pathological processes. However, the biological functions and mechanisms of tRFs in non-small cell lung cancer
Wenhan Yang +15 more
semanticscholar +1 more source